Renalytix

Traditional kidney measurements, such as estimated GFR and urinary albumin creatinine ratio, fail to identify patients at high risk of progressive kidney function decline.

A discussion with Dr. Eugene Wright, Medical Director for Performance Improvement at the *Charlotte Area Health Education Center* and former *Duke* consultant.

A 401-physician study demonstrates the value of *KidneyIntelX* testing, presented at the *National Kidney Foundation* 2021 Spring Clinical Meetings.

Data from 1,325 *CANVAS* participants with baseline diabetic kidney disease, scored using *KidneyIntelX*, was presented at the *International Society of Nephrology* World Congress of Nephrology.

Renalytix presents study results supporting repeat *KidneyIntelX* testing, reimbursement, and pharmaceutical collaborations.

Clinical findings on diabetic kidney disease were published in *Diabetologia*, the official journal of the *European Association for the Study of Diabetes*.

Renalytix plc American Depository Shares begin trading on the OTCQB Venture Market under the symbol *RNLXY*.

Company has Achieved Prerequisites for Growing Test Adoption with FDA Authorization, Clinical Outcomes Data, Inclusion in Clinical Guidelines, and Broad…

Renalytix plc, an artificial intelligence-enabled in vitro diagnostics company, announces updates on its operations.

Employees cite contributions to kidney care and collaboration with experts as reasons for joining and staying at Renalytix.

Kidneys matter, even though they don’t get much press. Kidneys are just as important to sustaining a healthy body as the heart and lungs. They filter the blood, expelling wastes and toxins from the body. They also make and regulate hormones and keep blood pressure in control. Most people

Renalytix uses *KidneyIntelX* technology to assess early-stage diabetic kidney disease risk, helping clinicians allocate resources and treatments to improve patient outcomes.